Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Trbovich, A. (57115127200)"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Serum β2-microglobulin as a marker of congenital toxoplasmosis and cytomegalovirus infection in preterm neonates
    (2008)
    Nešović-Ostojić, J. (15060276300)
    ;
    Klun, I. (55919253000)
    ;
    Vujanić, M. (25226202400)
    ;
    Trbovich, A. (57115127200)
    ;
    Djurković-Djaković, O. (6701811845)
    Background: Fetal serum β2-microglobulin (β2M) has been reported as a reliable indicator of fetal infectious diseases. Objectives: To evaluate serum β2M as a marker of congenital toxoplasmosis or cytomegalovirus (CMV) infection in neonates. Methods: β2M was retrospectively measured in 72 neonatal serum samples from preterm neonates. Of these, 32 originated from neonates with serological evidence of congenital toxoplasmosis (n = 12) and CMV infection (n = 20), while 40 samples from neonates in which both infections were serologically excluded served as controls. β2M levels were compared between the infection and control groups. Results: Mean (±SEM) β2M levels were significantly higher in the groups of neonates infected with Toxoplasma (5.64 ± 0.61 mg/l) (p = 0.014) and CMV (6.06 ± 0.66 mg/l) (p < 0.0001) than in the control group (3.80 ± 0.2). Against the cut-off level of 5 mg/l, β2M was normal in 36 of the 40 uninfected neonates examined, indicating a specificity of 90%. In contrast, it was elevated in 66.7% (8/12) and 65% (13/20) of the Toxoplasma and CMV-infected neonates, respectively, indicating an overall sensitivity of 66%. Conclusions: In the absence of urogenital disorders, an increase in β2M in neonates is likely to be infection-induced. We showed that serum β2M is increased in congenital toxoplasmosis and CMV infection in the first weeks of life. Copyright © 2008 S. Karger AG.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Serum β2-microglobulin as a marker of congenital toxoplasmosis and cytomegalovirus infection in preterm neonates
    (2008)
    Nešović-Ostojić, J. (15060276300)
    ;
    Klun, I. (55919253000)
    ;
    Vujanić, M. (25226202400)
    ;
    Trbovich, A. (57115127200)
    ;
    Djurković-Djaković, O. (6701811845)
    Background: Fetal serum β2-microglobulin (β2M) has been reported as a reliable indicator of fetal infectious diseases. Objectives: To evaluate serum β2M as a marker of congenital toxoplasmosis or cytomegalovirus (CMV) infection in neonates. Methods: β2M was retrospectively measured in 72 neonatal serum samples from preterm neonates. Of these, 32 originated from neonates with serological evidence of congenital toxoplasmosis (n = 12) and CMV infection (n = 20), while 40 samples from neonates in which both infections were serologically excluded served as controls. β2M levels were compared between the infection and control groups. Results: Mean (±SEM) β2M levels were significantly higher in the groups of neonates infected with Toxoplasma (5.64 ± 0.61 mg/l) (p = 0.014) and CMV (6.06 ± 0.66 mg/l) (p < 0.0001) than in the control group (3.80 ± 0.2). Against the cut-off level of 5 mg/l, β2M was normal in 36 of the 40 uninfected neonates examined, indicating a specificity of 90%. In contrast, it was elevated in 66.7% (8/12) and 65% (13/20) of the Toxoplasma and CMV-infected neonates, respectively, indicating an overall sensitivity of 66%. Conclusions: In the absence of urogenital disorders, an increase in β2M in neonates is likely to be infection-induced. We showed that serum β2M is increased in congenital toxoplasmosis and CMV infection in the first weeks of life. Copyright © 2008 S. Karger AG.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback